TY  - JOUR
A1  - van der Valk, Ralf J. P.
A1  - Kreiner-Moller, Eskil
A1  - Kooijman, Marjolein N.
A1  - Guxens, Monica
A1  - Stergiakouli, Evangelia
A1  - Saaf, Annika
A1  - Bradfield, Jonathan P.
A1  - Geller, Frank
A1  - Hayes, M. Geoffrey
A1  - Cousminer, Diana L.
A1  - Koerner, Antje
A1  - Thiering, Elisabeth
A1  - Curtin, John A.
A1  - Myhre, Ronny
A1  - Huikari, Ville
A1  - Joro, Raimo
A1  - Kerkhof, Marjan
A1  - Warrington, Nicole M.
A1  - Pitkanen, Niina
A1  - Ntalla, Ioanna
A1  - Horikoshi, Momoko
A1  - Veijola, Riitta
A1  - Freathy, Rachel M.
A1  - Teo, Yik-Ying
A1  - Barton, Sheila J.
A1  - Evans, David M.
A1  - Kemp, John P.
A1  - St Pourcain, Beate
A1  - Ring, Susan M.
A1  - Smith, George Davey
A1  - Bergstrom, Anna
A1  - Kull, Inger
A1  - Hakonarson, Hakon
A1  - Mentch, Frank D.
A1  - Bisgaard, Hans
A1  - Chawes, Bo Lund Krogsgaard
A1  - Stokholm, Jakob
A1  - Waage, Johannes
A1  - Eriksen, Patrick
A1  - Sevelsted, Astrid
A1  - Melbye, Mads
A1  - van Duijn, Cornelia M.
A1  - Medina-Gomez, Carolina
A1  - Hofman, Albert
A1  - de Jongste, Johan C.
A1  - Taal, H. Rob
A1  - Uitterlinden, Andre G.
A1  - Armstrong, Loren L.
A1  - Eriksson, Johan
A1  - Palotie, Aarno
A1  - Bustamante, Mariona
A1  - Estivill, Xavier
A1  - Gonzalez, Juan R.
A1  - Llop, Sabrina
A1  - Kiess, Wieland
A1  - Mahajan, Anubha
A1  - Flexeder, Claudia
A1  - Tiesler, Carla M. T.
A1  - Murray, Clare S.
A1  - Simpson, Angela
A1  - Magnus, Per
A1  - Sengpiel, Verena
A1  - Hartikainen, Anna-Liisa
A1  - Keinanen-Kiukaanniemi, Sirkka
A1  - Lewin, Alexandra
A1  - Alves, Alexessander Da Silva Couto
A1  - Blakemore, Alexandra I. F.
A1  - Buxton, Jessica L.
A1  - Kaakinen, Marika
A1  - Rodriguez, Alina
A1  - Sebert, Sylvain
A1  - Vaarasmaki, Marja
A1  - Lakka, Timo
A1  - Lindi, Virpi
A1  - Gehring, Ulrike
A1  - Postma, Dirkje S.
A1  - Ang, Wei
A1  - Newnham, John P.
A1  - Lyytikainen, Leo-Pekka
A1  - Pahkala, Katja
A1  - Raitakari, Olli T.
A1  - Panoutsopoulou, Kalliope
A1  - Zeggini, Eleftheria
A1  - Boomsma, Dorret I.
A1  - Groen-Blokhuis, Maria
A1  - Ilonen, Jorma
A1  - Franke, Lude
A1  - Hirschhorn, Joel N.
A1  - Pers, Tune H.
A1  - Liang, Liming
A1  - Huang, Jinyan
A1  - Hocher, Berthold
A1  - Knip, Mikael
A1  - Saw, Seang-Mei
A1  - Holloway, John W.
A1  - Melen, Erik
A1  - Grant, Struan F. A.
A1  - Feenstra, Bjarke
A1  - Lowe, William L.
A1  - Widen, Elisabeth
A1  - Sergeyev, Elena
A1  - Grallert, Harald
A1  - Custovic, Adnan
A1  - Jacobsson, Bo
A1  - Jarvelin, Marjo-Riitta
A1  - Atalay, Mustafa
A1  - Koppelman, Gerard H.
A1  - Pennell, Craig E.
A1  - Niinikoski, Harri
A1  - Dedoussis, George V.
A1  - Mccarthy, Mark I.
A1  - Frayling, Timothy M.
A1  - Sunyer, Jordi
A1  - Timpson, Nicholas J.
A1  - Rivadeneira, Fernando
A1  - Bonnelykke, Klaus
A1  - Jaddoe, Vincent W. V.
T1  - A novel common variant in DCST2 is associated with length in early life and height in adulthood
JF  - Human molecular genetics
N2  - Common genetic variants have been identified for adult height, but not much is known about the genetics of skeletal growth in early life. To identify common genetic variants that influence fetal skeletal growth, we meta-analyzed 22 genome-wide association studies (Stage 1; N = 28 459). We identified seven independent top single nucleotide polymorphisms (SNPs) (P < 1 x 10(-6)) for birth length, of which three were novel and four were in or near loci known to be associated with adult height (LCORL, PTCH1, GPR126 and HMGA2). The three novel SNPs were followed-up in nine replication studies (Stage 2; N = 11 995), with rs905938 in DC-STAMP domain containing 2 (DCST2) genome-wide significantly associated with birth length in a joint analysis (Stages 1 + 2; beta = 0.046, SE = 0.008, P = 2.46 x 10(-8), explained variance = 0.05%). Rs905938 was also associated with infant length (N = 28 228; P = 5.54 x 10(-4)) and adult height (N = 127 513; P = 1.45 x 10(-5)). DCST2 is a DC-STAMP-like protein family member and DC-STAMP is an osteoclast cell-fusion regulator. Polygenic scores based on 180 SNPs previously associated with human adult stature explained 0.13% of variance in birth length. The same SNPs explained 2.95% of the variance of infant length. Of the 180 known adult height loci, 11 were genome-wide significantly associated with infant length (SF3B4, LCORL, SPAG17, C6orf173, PTCH1, GDF5, ZNFX1, HHIP, ACAN, HLA locus and HMGA2). This study highlights that common variation in DCST2 influences variation in early growth and adult height.
Y1  - 2015
U6  - https://doi.org/10.1093/hmg/ddu510
SN  - 0964-6906
SN  - 1460-2083
VL  - 24
IS  - 4
SP  - 1155
EP  - 1168
PB  - Oxford Univ. Press
CY  - Oxford
ER  - 
TY  - JOUR
A1  - Neuschäfer-Rube, Frank
A1  - Oppermann, Martin
A1  - Möller, Ulrike
A1  - Böer, Ulrike
A1  - Püschel, Gerhard Paul
T1  - Agonist-induced phosphorylation by G protein-coupled receptor kinases of the EP4 receptor carboxyl-terminal domain in an EP3/EP4 prostaglandin E(2) receptor hybrid
N2  - Prostaglandin E(2) receptors (EP-Rs) belong to the family of heterotrimeric G protein-coupled ectoreceptors with seven transmembrane domains. They can be subdivided into four subtypes according to their ligand-binding and G protein-coupling specificity: EP1 couple to G(q), EP2 and EP4 to G(s), and EP3 to G(i). The EP4-R, in contrast to the EP3beta-R, shows rapid agonist-induced desensitization. The agonist-induced desensitization depends on the presence of the EP4-R carboxyl-terminal domain, which also confers desensitization in a G(i)-coupled rEP3hEP4 carboxyl-terminal domain receptor hybrid (rEP3hEP4-Ct-R). To elucidate the possible mechanism of this desensitization, in vivo phosphorylation stimulated by activators of second messenger kinases, by prostaglandin E(2), or by the EP3-R agonist M&B28767 was investigated in COS-7 cells expressing FLAG-epitope-tagged rat EP3beta-R (rEP3beta-R), hEP4-R, or rEP3hEP4- Ct-R. Stimulation of protein kinase C with phorbol-12-myristate-13-acetate led to a slight phosphorylation of the FLAG- rEP3beta-R but to a strong phosphorylation of the FLAG-hEP4-R and the FLAG-rEP3hEP4-Ct-R, which was suppressed by the protein kinase A and protein kinase C inhibitor staurosporine. Prostaglandin E(2) stimulated phosphorylation of the FLAG- hEP4-R in its carboxyl-terminal receptor domain. The EP3-R agonist M&B28767 induced a time- and dose-dependent phosphorylation of the FLAG-rEP3hEP4-Ct-R but not of the FLAG-rEP3beta-R. Agonist-induced phosphorylation of the FLAG- hEP4-R and the FLAG-rEP3hEP4-Ct-R were not inhibited by staurosporine, which implies a role of G protein-coupled receptor kinases (GRKs) in agonist-induced receptor phosphorylation. Overexpression of GRKs in FLAG-rEP3hEP4-Ct-R- expressing COS-7 cells augmented the M&B28767-induced receptor phosphorylation and receptor sequestration. These findings indicate that phosphorylation of the carboxyl-terminal hEP4-R domain possibly by GRKs but not by second messenger kinases may be involved in rapid agonist-induced desensitization of the hEP4-R and the rEP3hEP4-Ct-R.
Y1  - 1999
SN  - 1521-0111
ER  - 
TY  - JOUR
A1  - Thonicke, Mady
A1  - Frank, Ulrike
T1  - Biofeedback in der Dysphagietherapie
BT  - Unterstützung therapeutischer Maßnahmen durch Oberflächen-Elektromyographie (sEMG)
JF  - Spektrum Patholinguistik (Band 8) - Schwerpunktthema: Besonders behandeln? : Sprachtherapie im Rahmen primärer Störungsbilder
KW  - Patholinguistik
KW  - Sprachtherapie
KW  - geistige Behinderung
KW  - primär progessive Aphasie
KW  - patholinguistics
KW  - speech therapy
KW  - mental deficiency
KW  - primary progessive aphasia
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-79891
SP  - 243
EP  - 247
PB  - Universitätsverlag Potsdam
CY  - Potsdam
ER  - 
TY  - JOUR
A1  - Frank, Ulrike
A1  - Frank, Katrin
T1  - COVID-19
BT  - neue Herausforderungen in der Dysphagie- und Atemtherapie
BT  - new challenges in dysphagia and respiratory therapy
JF  - Der Nervenarzt : Organ der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde ; Mitteilungsblatt der Deutschen Gesellschaft für Neurologie
N2  - Eine COVID-19-Erkrankung kann zu schweren Krankheitsverläufen mit multiplen Organbeteiligungen und respiratorischen und neurologischen Funktionseinschränkungen führen. Schluckstörungen (Dysphagien) können in dieser Patientengruppe durch primäre Schädigungen des zentralen und peripheren neuronalen Netzwerkes der Schluckfunktion entstehen, aber auch bedingt durch die häufig längere intensivmedizinische Behandlung und Beatmung. Erste klinische Befunde zeigen persistierende Dysphagien im Rahmen des Post-COVID-Syndroms („Long-COVID“), sodass die Patienten auch längerfristige Maßnahmen zur Rehabilitation einer sicheren und suffizienten oralen Nahrungsaufnahme benötigen. Daher sollte in die Behandlung von COVID-19-Patienten ein strukturiertes erkrankungsspezifisches Monitoring in Bezug auf Dysphagiesymptome integriert werden, und atemtherapeutische Maßnahmen zur Regulation von Husteneffektivität und Atem-Schluck-Koordination sollten auch bei diesen Patienten essenzieller Bestandteil des Dysphagiemanagements sein. Herausforderungen ergeben sich dabei einerseits durch die erforderlichen Anpassungen etablierter Behandlungsstandards an den Infektionsschutz. Zudem müssen Auswahl und Durchführungsintensität therapeutischer Maßnahmen an die Kapazitäten und die spezifische Pathophysiologie der COVID-19- und Long-COVID-Patienten angepasst werden, um weitere funktionelle Verschlechterungen zu vermindern.
N2  - Coronavirus disease 2019 (COVID-19) can lead to severe disease courses with multiple organ involvement, respiratory and neurological functional impairments. Swallowing disorders (dysphagia) in this patient group can result from primary damage to the central and peripheral neuronal swallowing network but also from the frequently prolonged intensive care treatment and mechanical ventilation. Clinical observations indicate persistence of dysphagia in post-acute COVID-19 syndrome (long COVID), so that these patients probably also need long-term interventions for rehabilitation of safe and sufficient oral feeding. Therefore, structured disease-specific monitoring of dysphagia symptoms should be integrated into the treatment of COVID-19 patients and respiratory therapy should be an essential part of dysphagia management to re-establish cough effectiveness and breathing-swallowing coordination. Challenges arise from necessary adjustments to established treatment standards to prevent infections. Furthermore, the selection and intensity of therapeutic measures have to be adapted to the capacities and the specific pathophysiology of COVID-19 and long COVID patients to prevent further functional deterioration.
KW  - Long COVID
KW  - Fatigue
KW  - Post intensive care syndrome (PICS)
KW  - Laryngeal functions
KW  - Laryngeale Funktionen
KW  - Hypoxemia
KW  - Hypoxämie
KW  - Long-COVID
Y1  - 2021
U6  - https://doi.org/10.1007/s00115-021-01162-5
SN  - 0028-2804
SN  - 1433-0407
VL  - 93
IS  - 2
SP  - 167
EP  - 174
PB  - Springer
CY  - New York
ER  - 
TY  - JOUR
A1  - Düsterhöft, Stefanie
A1  - Frank, Ulrike
T1  - Das PNF-Konzept
BT  - Anwendung in der orofacialen Therapie
JF  - Spektrum Patholinguistik
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus-54306
SN  - 1869-3822
SN  - 1866-9433
IS  - 4
SP  - 171
EP  - 183
ER  - 
TY  - JOUR
A1  - Düsterhöft, Stefanie
A1  - Frank, Ulrike
T1  - Das PNF-Konzept Anwendung in der orofacialen Therapie
Y1  - 2011
ER  - 
TY  - JOUR
A1  - Sticher, Heike
A1  - Czepluch, Christine
A1  - Mätzener, Flurina
A1  - Wilmes, Stefanie
A1  - Hadert, Sandra
A1  - Frank, Ulrike
A1  - Mäder, Mark
T1  - Dekanülierungsmanagement bei Patienten mit respiratorischen Beeinträchtigungen und Dysphagie
JF  - Spektrum Patholinguistik
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus-54277
SN  - 1869-3822
SN  - 1866-9433
IS  - 4
SP  - 141
EP  - 142
ER  - 
TY  - JOUR
A1  - Sticher, Heike
A1  - Czepluch, Christine
A1  - Mätzener, Flurina
A1  - Wilmes, Stefanie
A1  - Hadert, Sandra
A1  - Frank, Ulrike
A1  - Mäder, Mark
T1  - Dekanülierungsmanagment bei Patienten mit respiratorischen Beeinträchtigungen und Dysphagie
Y1  - 2011
ER  - 
TY  - JOUR
A1  - Posse, Dorothea
A1  - Frank, Ulrike
T1  - Der Einfluss des Lee Silverman Voice Treatment (LSVT) auf die Hypernasalität bei Dysarthrie
JF  - Spektrum Patholinguistik
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus-54313
SN  - 1869-3822
SN  - 1866-9433
IS  - 4
SP  - 185
EP  - 187
ER  - 
TY  - JOUR
A1  - Posse, Dorothea
A1  - Frank, Ulrike
T1  - Der Einfluss des Lee Silverman Voice Treatment (LSVT) auf die Hypernasalität bei Dysarthrie
Y1  - 2011
ER  -